Assessing the Quality of Life of Children’s with Acute Respiratory Tract Infections

2021 ◽  
Vol 14 (1) ◽  
pp. 32-40
Author(s):  
Jothieswari Dhamotharan ◽  
Durga Prasad Dinesh Kumar ◽  
Lakshmi Raj Sulochana Rajasekaran ◽  
Vinnayak Mondal ◽  
Rachana Panner Selvan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Acute Respiratory Tract Infections ◽  
Tract Infections

Nasal disease and quality of life in athletes

2018 ◽  
Vol 132 (9) ◽  
pp. 812-815
Author(s):  
A C Walker ◽  
P Surda ◽  
M Rossiter ◽  
S A Little
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Nasal Symptoms ◽  
Nasal Disease ◽  
Upper Respiratory ◽  
Tract Infections

AbstractObjectivesNasal disease imposes a significant disease burden upon the individual in the general population, but is relatively under studied in athletes. This study sought to define the frequency of nasal symptoms in the active population, and to quantify the impact of these symptoms on quality of life and on the frequency of upper respiratory tract infections.ResultsA total of 296 participants completed the study (246 athletes and 50 sedentary controls). Nasal symptoms were significantly more frequent in the active group than in the sedentary controls (70 per cent vs 52 per cent). Upper respiratory tract infections were significantly more common in athletes with regular nasal symptoms than in athletes without nasal symptoms. Quality-of-life scores, as measured by the 22-item Sino-Nasal Outcome Test, were significantly worse in athletes with regular nasal symptoms.ConclusionThis study suggests that regular exercise is associated with a significant increase in the prevalence of troubling nasal symptoms, and nasal symptoms in athletes are associated with increased susceptibility to upper respiratory tract infections. Quality of life was negatively affected, confirming the importance of nasal health to athlete welfare.

Quality of life in patients with smell loss due to upper respiratory tract infections

2011 ◽  
Vol 32 (6) ◽  
pp. 504-510 ◽  
Author(s):  
Adolfo Toledano ◽  
Gil Rodríguez ◽  
Ana María Martín ◽  
Tomás Onrubia ◽  
Néstor Galindo
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Smell Loss

scholarly journals Fever Management in Children with Acute Respiratory Tract Infections

Doctor Ru ◽  
2021 ◽  
Vol 20 (10) ◽  
pp. 6-11
Author(s):  
N.A. Geppe ◽  
◽  
N.G. Kolosova ◽  
A.B. Malakhov ◽  
M.D. Velikoretskaya ◽  
...  
Keyword(s):  
Body Temperature ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Efficacy And Safety ◽  
Mean Body Temperature ◽  
Play Activity ◽  
Acute Respiratory Tract Infections ◽  
Study Results ◽  
Tract Infections

Study Objective: To obtain additional information on efficacy and safety of the use of a fixed combination of Paracetamol and Ibuprofen in children with fever associated with acute respiratory tract infection (ARTI). Study Design: Multicentre open-label cohort observational study. Materials and Methods. 242 children aged 3 to 12 years old (mean age: 6.3 ± 2.7 years old) with ARTI and fever participated in the study. When the body temperature was 38.1°С and higher, we used an antipyretic combination: a dispersible tablet containing 100mg Ibuprofen and 125mg Paracetamol (Ibuclin Junior®), 1 tablet 3 times daily in children aged 3 to 6 years old, and up to 6 tablets in children aged 7 to 12 years old (max. for 4 days). We evaluated the clinical efficacy and safety of the antipyretic therapy, parents’ satisfaction (using the Integrative Medicine Patient Satisfaction Scale), and quality of child’s life (sleep, appetite, play activity). Study Results. During examination, mean body temperature was 38.8°С (mostly 38.6 to 39.0°С). On day 1, 2, 3, and 4, antipyretic therapy was needed by 242 (100%), 168 (69.4%), 65 (26.9%), and 2 (0.8%) children, respectively. During first two days, patients took on an average 2 tablets, then 1 tablet. After the first dose, the normal body temperature (< 37.2°C) in 1, 4, 24, 48, and 72 hours was observed in 14%, 62%, 43.4%, 71.5%, and 98% of patients; while the mean body temperature was 37.6; 37.1; 37.6; 37.0, and 36.5°С, respectively. No adverse events or therapy failures were recorded during the study. In 48 and 72 hours after initiation of therapy, a share of parents who were “completely satisfied” and “satisfied” with the medicinal product was 86,4% and 95,9%, respectively. Poor quality of child’s life correlated with severity of fever; in 96 hours after therapy initiation, sleep and play activity normalised in over 90% of patients, appetite got better in 77%. Conclusion. Study results demonstrate high efficacy (even after the first dose) and safety of a combination product (dispersible tablets containing Ibuprofen and Paracetamol) for the management of fever in children with ARTI; and the product can be recommended for wide use in paediatrics. Keywords: children, acute respiratory tract infections, fever, Paracetamol, Ibuprofen.

scholarly journals INFLAMMATION AS A CAUSE OF COUGH AND COMPLICATIONS: ROLE OF MODERN MUCOLYTICS

2021 ◽  
Vol 29 (2) ◽  
pp. 41-46
Author(s):  
M. M. Ostovskiy
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Controlled Trial ◽  
Lower Respiratory Tract Infections ◽  
Observation Study ◽  
Tract Infections ◽  
The Impact

A literature review regarding pharmacodynamics of mucolytic compound erdosteine (Ermucin by Edmond Pharma) has been presented in current publication. Mucolytic effect of this compound is based on the braking of disulfuric bonds, tiding the glycoproteine fibers, resulting in encreased elasticity and decreased viscosity of sputum. Erdosteine metabolites improve the effectiveness of muco-ciliary clearance of purulent and mucopurulent low respiratory tract secretions. Anti-inflammatory effect of erdosteine is mediated through the suppression of pro-inflammatory cytokines synthesis, such as IL-6 and IL-8, directly involved in neutrophilic immune response in bronchial tree and lung parenchyma. Additionally, erdostein acts as reactive oxygen species scavenger, preventing its local formation, decreasing 8-isoprostane level as a marker of lipid peroxidation. Erdostein, being used in 8-months courses, allows not only to manage COPD exacerbation, but also prevents it, improving the quality of life of the patients and modifying diseases outcomes. The impact of erdostein on the rate and duration of COPD exacerbations has been proved in randomized placebo-controlled trial RESTORE. The evidence from this study was used as a rationale for inclusion of erdosteine in 2019 GOLD Guidelines and national COPD guidelines. The results of the own limited open-label observation study of erdosteine efficacy in COVID-19 associated pneumonia, performed following the discharge of patients from Ivano-Frankivsk regional phthisiopulmonology center from 1 Jul 2020 till 25 Oct 2020 are presented in this article. The efficacy or erdosteine after one month therapy has been proved in study patients. On Day 30 of erdosteine therapy mMRC dyspnea score significantly decreased in 30.7 % of patients on the background of improved quality of life assessed by SGRQ questionnaire. The dosage and administration of erdosteine for management of cough in acute lower respiratory tract infections, COPD/chronic bronchitis exacerbations, exacerbation prevention and cough modification, recovery of physical activity in COVID-19 convalescents with secondary bacterial pneumonia, have been presented. Key words: lower respiratory tract infections, mucolytic therapy, erdosteine.

Sign in / Sign up

Export Citation Format

Share Document